COGNITE
15.5.2024 08:01:29 CEST | Business Wire | Press release
Cognite, a globally recognized leader in industrial software, announced today that its flagship Industrial DataOps product, Cognite Data Fusion®, is now available on Google Cloud in Saudi Arabia. This strategic collaboration combines Cognite's leading data management and secure, trustworthy artificial intelligence (AI) with Google Cloud's powerful infrastructure and data analytics capabilities, enabling customers to seamlessly migrate their data to the cloud, ensuring scalability, flexibility, and security while empowering customers in Saudi Arabia with simple access to their complex industrial data.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240513716575/en/
Cognite Data Fusion® Now Available on Google Cloud in Saudi Arabia (Graphic: Business Wire)
Cognite Data Fusion will deploy its own comprehensive contextualization and generative AI (gen AI) capabilities purpose-built for complex industrial data on top of Google Cloud's advanced AI and machine learning tools—a powerful combination to deliver actionable insights, improve operational efficiency, and drive digital transformation across industries such as energy, manufacturing, and logistics.
"We are thrilled to bring Cognite Data and AI offerings to Google Cloud customers in Saudi Arabia," said Dr. Francois Laborie, Executive Vice President, Cognite. "This is a significant milestone in our partnership, and as well as our commitment to the Kingdom. The power of data and AI, from Cognite and Google Cloud, enables industry transformation via solutions that deliver business value to our customers."
"We are excited to partner with Cognite to bring their advanced industrial data platform to Google Cloud customers in Saudi Arabia," said Abdul Rahman Al Thehaiban, Managing Director, Middle East, Turkey and Africa, Google Cloud. "By leveraging Google Cloud's scalable and secure infrastructure, Cognite Data Fusion will enable customers to harness the power of their data to make smarter business decisions and accelerate their digital transformation journey."
Cognite Data Fusion’s best-of-breed gen AI capabilities tailored for industrial use cases enable customers to generate synthetic data, simulate scenarios, and optimize operations, ultimately improving decision-making and business outcomes.
In the Kingdom and the wider MENA region, Cognite Data Fusion is brought to the market by CNTXT, a joint venture between Saudi Aramco and Cognite. This partnership combines CNTXT's deep understanding of the regional industrial landscape with Cognite's cutting-edge technology, providing customers with tailored solutions that address their specific needs and challenges. "Cognite Data Fusion is poised to revolutionize how the Kingdom’s industries harness insights from their data. Cognite Data Fusion offers world-leading gen AI capabilities tailored for industrial sectors", said Abdullah Jarwan, CEO of CNTXT.
Cognite Data Fusion on Google Cloud is now available for customers in Saudi Arabia. For more information, visit www.cntxt.com.
About CNTXT:
CNTXT, a joint venture between Saudi Aramco and Cognite, is a leading digital transformation company headquartered in Riyadh, Saudi Arabia. With a mission to empower organizations through technology and innovation, CNTXT leverages strategic partnerships and a network of resellers to accelerate digital transformation across public and private sectors in the Kingdom.
About Cognite
Cognite makes Generative AI work for industry. Leading energy, manufacturing, and power and renewables enterprises choose Cognite to deliver secure, trustworthy, and real-time data to transform their asset-heavy operations to be safer, more sustainable and more profitable. Cognite provides a user-friendly, secure, and scalable industrial DataOps platform, Cognite Data Fusion®, that makes it easy for all decision-makers, from the field to remote operations centers, to access and understand complex industrial data, collaborate in real-time, and build a better tomorrow. Visit us at www.cognite.ai and follow us on LinkedIn and X (Twitter).
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240513716575/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release
Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom